Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism

被引：13

作者：

Franceschini, N ^{[1
]}

Joy, MS ^{[1
]}

Kshirsagar, A ^{[1
]}

机构：

[1] Univ N Carolina, Sch Med, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2003年 / 12卷 / 08期

关键词：

AMG; 073; calcimimetic; calcium-sensing receptor; cinacalcet HCl; primary hyperparathyroidism; secondary hyperparathyroidism;

D O I：

10.1517/eoid.12.8.1413.21770

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Cinacalcet HCl (AMG 073) is an investigational oral calcimimetic drug currently being evaluated for the treatment of primary and secondary hyperparathyroidism (HPT). Calcimimetics bind to the calcium-sensing receptors of the parathyroid glands and lower the sensitivity for receptor activation by extracellular calcium, thereby diminishing parathyroid hormone release. Cinacalcet HCl has demonstrated efficacy in controlling the hypercalcaemia of severe primary HPT and in reducing parathyroid hormone levels in patients with secondary HPT. Asymptomatic dose-dependent hypocalcaemia has occurred in some clinical trials. This drug has a favourable pharmacokinetic profile compared to its precursors and will prove useful as an additional/ alternative agent in patients with primary and secondary HPT.

引用

页码：1413 / 1421

页数：9

共 44 条

[1]

Adami S, 2002, J BONE MINER RES, V17, pN18

[2]

Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century [J].

Bilezikian, JP ;

Potts, JT ;

El-Hajj Fuleihan, G ;

Kleerekoper, M ;

Neer, R ;

Peacock, M ;

Rastad, J ;

Silverberg, SJ ;

Udelsman, R ;

Wells, SA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12) :5353-5361

[3]

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].

Block, GA ;

Hulbert-Shearon, TE ;

Levin, NW ;

Port, FK .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617

[4]

Block GA, 2002, J AM SOC NEPHROL, V13, p572A

[5]

CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].

BROWN, EM ;

GAMBA, G ;

RICCARDI, D ;

LOMBARDI, M ;

BUTTERS, R ;

KIFOR, O ;

SUN, A ;

HEDIGER, MA ;

LYTTON, J ;

HEBERT, SC .

NATURE, 1993, 366 (6455) :575-580

[6]

MOLECULAR MECHANISMS UNDERLYING THE SENSING OF EXTRACELLULAR CA2+ BY PARATHYROID AND KIDNEY-CELLS [J].

BROWN, EM ;

POLLAK, M ;

HEBERT, SC .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (05) :523-531

[7]

Chin J, 2000, J AM SOC NEPHROL, V11, P903, DOI 10.1681/ASN.V115903

[8]

Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent [J].

Collins, MT ;

Skarulis, MC ;

Bilezikian, JP ;

Silverberg, SJ ;

Spiegel, AM ;

Marx, SJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) :1083-1088

[9]

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey [J].

Coresh, J ;

Astor, BC ;

Greene, T ;

Eknoyan, G ;

Levey, AS .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) :1-12

[10]

Drueke T., 2001, Journal of the American Society of Nephrology, V12, p764A

← 1 2 3 4 5 →